

Claim 51 (NEW). A pharmaceutical composition for neuropathy comprising an effective amount of a compound or a salt thereof which activates a PACAP receptor or antagonizes binding of PACAP to a PACAP receptor.

Claim 52 (NEW). A pharmaceutical composition for neuropathy comprising an effective amount of PACAP agonists.

B.1
Claim 53 (NEW). A pharmaceutical composition for Alzheimer's disease comprising an effective amount of PACAP agonists.

Claim 54 (NEW). A method for treating neuropathy which comprises administering an effective amount of compounds or a salt thereof which activates a PACAP receptor or antagonizes binding of a PACAP to a PACAP receptor to mammals.

Claim 55 (NEW). A method for treating neuropathy which comprises administering an effective amount of PACAP agonists to mammals.

Claim 56 (NEW). A method for treating Alzheimer's disease which comprises administering an effective amount of PACAP agonists to mammals.


REMARKS

New claims 51-56 have been added by virtue of this amendment. No new matter has been added by virtue of these amendments and their entry is respectfully requested. Support for the new claims is found throughout the specification. For example, support for claims 51 to 53 can be found on page 7, lines 6 to 26 through to page 9, lines 11 to 15; page 71, lines 24 to 26 through to page 74 lines 1 to 2; and Examples 1 through 8. Support for claims 54 to 56 can be found on page 64, lines 22 to 26 through to page 71, lines 1 to 23.

Early consideration and allowance of the application are earnestly solicited.

Respectfully submitted,

DATE: March²⁶, 2003



David G. Conlin (Reg. No. 27,026)
EDWARDS & ANGELL, LLP
P.O. Box 9169
Boston, MA 02209

Tel. No.: (617) 439-4444
Fax No.: (617) 439-4170